Myocarditis is a disease marked by inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral infections, autoimmune diseases, environmental toxins, and adverse reactions to medications that reach the heart. The prognosis is variable but chronic heart failure is the major long term complication. It affects the heart muscle and heart's electrical system, reducing the heart's ability to pump and causing rapid or abnormal heart rhythms (arrhythmias). Symptoms include achy feeling in the chest, difficulty in breathing when resting, rapid or abnormal heartbeat, fluid retention with swelling of legs, ankles and feet, shortness of breath, at rest or during physical activity, and fatigue.
Long-term consequence of myocarditis is chronic dilated cardiomyopathy, and the pathways that lead to myocardial fibrosis and chronic cardiomyopathy are poorly understood. Global incidence of the myocarditis disease are not yet known because the tests to identify viruses in heart tissue are not widely available. Most of the reported cases are from North America and Europe. Based on the study done by University of Calgary, men are two-times more likely to develop myocardial fibrosis following myocarditis than women and in patients younger than 40 years. There has been no cases of the disease have been reported to date due to genetic factors from the same family and inter-human transmission cases. Numerous polymorphisms have been identified that either influence an individual’s ability to clear infection or alter the function of the immune response
High rate of growth of the myocarditis disease market can be attributed to the entry of novel, highly priced therapies and high unmet needs. No specific approved drug or vaccine has been available to treat or prevent myocarditis disease till date. Patients are treated only by administering prophylaxis drugs. Key players are focusing on the development of new drugs and vaccines with better efficacy. Evotec AG and Oxford University announced a partnership for LAB282, the £13m drug discovery partnership project, for the development of new therapeutics such as myocarditis, which in turn is likely to fuel the global myocarditis disease market in the near future. However, the high price of prophylaxis drugs and a lack of return of investment are likely to hamper the global myocarditis disease market during the forecast period.
There are several unmet needs in global myocarditis disease market, which create significant opportunities for existing players and new entrants in the global market. Recombint Peptides, vaccines and small molecule provide ample opportunities for players operating in the global myocarditis disease market. Recent ongoing developments in myocarditis disease drugs such as Evotec AG LAB282, CEL-SCI's CEL-1000, Swedish Orphan Biovitrum AB uncovers the potential of these drugs. Competitive activity is increasing as larger companies realize the rewards of investing in orphan therapeutics. High unmet needs and low competition in several regions is expected to attract more companies to the market in the near future. The clinical studies for the molecules receiving the funding from the U.S. government for the rare disease lead to increase in development of molecules.
The global myocarditis disease market can be segmented based on drug type, dosage form, molecule type and geography. In terms of drug type, it can be segmented based on antibiotics, anti-inflammatory diuretics and branded drugs. Treatment is to reduce swelling and remove excess water from the body.
In terms of dosage form, the injectable form segment led the market, in terms of revenue, in 2017. The segment is projected to maintain its dominant position in the market during the forecast period. In terms of molecule type, small molecule was the leading segment of the market in 2017. It is likely to hold a leading share of the market during the forecast period.
In terms of geography, North America held a major share of the myocarditis disease therapeutics market in 2017. Increasing prevalence of myocarditis disease among infants and the rise in awareness about the effect of the infection are likely to drive the market in North America. The market in Europe and Asia Pacific is projected to gain market share during the forecast period and is likely to account for a significant share of the market, in terms of revenue, in the near future. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and financial support for research and development for antiviral drugs in countries such as Brazil, South Africa, etc. are likely to boost the market in Latin America and Middle East and Africa.
Players operating in the global myocarditis disease market are CEL-SCI Corp, Evotec AG, Swedish Orphan Biovitrum AB, ARMO Biosciences and Novartis. These players are adopting organic and in-organic growth strategies to expand their product offerings, strengthen their geographical reach, increase customer base, and gain market share.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.